Denosumab biosimilars

Fully human IgG2 monoclonal antibody of about 147 kDa, produced in Chinese hamster ovary cells. The IgG2 subclass gives it little effector function, which is intended: its action is neutralisation, not cell killing.

Binds RANK ligand and prevents it from activating RANK on osteoclasts and their precursors, so osteoclast formation, function and survival fall and bone resorption is suppressed. The effect is rapid and reversible; bone turnover markers return toward baseline within months of stopping.

Subcutaneous bioavailability about 62%, peak concentrations around 10 days after dosing, half-life about 26 days. Pharmacokinetics are non-linear at low doses because of target-mediated clearance, which is why the pharmacodynamic marker CTX is used alongside PK in comparative studies.

Osteoporosis: 60 mg every six months by pre-filled syringe. Skeletal events in bone metastases: 120 mg every four weeks by vial. Two brand names per product, one for each dose, are the norm in the US and EU, so a single biosimilar appears in the register under two names.

• Postmenopausal osteoporosis at high risk of fracture
• Osteoporosis in men, and bone loss from hormone ablation therapy in prostate and breast cancer
• Glucocorticoid-induced osteoporosis
• Prevention of skeletal-related events in bone metastases from solid tumours and multiple myeloma
• Giant cell tumour of bone
• Hypercalcaemia of malignancy refractory to bisphosphonates

Anti-drug antibodies are rare, under 1%, and neutralising antibodies have not been detected in reference-product trials. Comparative programmes rely on analytical similarity, a pharmacokinetic and pharmacodynamic study in healthy volunteers using CTX suppression, and a comparative efficacy study in postmenopausal osteoporosis using lumbar spine bone mineral density at one year.

Prolia was licensed by FDA on 1 June 2010 (BLA 125320) and authorised in the EU on 26 May 2010; Xgeva followed in November 2010 and July 2011. Amgen's key patents expired in the EU in June 2025 and in the US in February 2025, and settlement agreements set US launch dates through 2025 and 2026. The first biosimilar pair, Jubbonti and Wyost, was approved by FDA in March 2024 with interchangeability from the day of licensure.

Sources: Purple Book (S016), EMA medicines data (S017); patent and settlement dates from company and press reports.

Denosumab is the most crowded biosimilar entry of the decade: ten FDA-approved products and twelve EU products within eighteen months, nearly all interchangeable in the US. For a developer the science is well trodden, so the differentiators are speed, the two-presentation portfolio, and commercial partnering. In India the first permission went to Intas in January 2018, with Enzene, Reliance, Hetero and Lupin following, and in the UAE Sandoz and Accord registered in 2025 and 2026.